Keyword → CVS

Wall Street Volatility Spikes as Stagflation Fears Grip Investors

Markets are grappling with a potentially dangerous combination of slowing economic growth and rising energy costs. Investors are increasingly worried that the U.S. economy could face stagflation, a scenario where inflation remains elevated even as growth weakens. The outlook has triggered sharp moves across equities, commodities and bond markets as traders reposition portfolios to navigate an uncertain macroeconomic environment.

Walmart Beats Q4 Estimates but Soft Full-Year Guidance Rattles Investors

Walmart delivered better-than-expected fourth-quarter earnings and revenue on Thursday, fueled by robust e-commerce growth and expanding advertising revenue, but its full-year earnings outlook of $2.75 to $2.85 per share fell short of Wall Street's consensus of $2.96, sending shares modestly lower in premarket trading and raising questions about the pace of margin expansion under its new chief executive.

Philips Reports 2025 Results With Margin Expansion and 2026 Outlook Targets

Royal Philips published its full-year 2025 financial results, highlighting accelerated growth, expanding profit margins and robust cash flow. The company also unveiled strategic targets for 2026-2028, emphasizing innovation and operational efficiency across health technology segments.

Organic Snacks IPO Sees Strong Debut With Double-Digit Gains

Once Upon a Farm PBC’s shares surged in their trading debut on Friday after the organic snacks maker raised nearly $198 million in an initial public offering. The double-digit gain highlights strong investor appetite for consumer brands with sustainability angles, marking one of the most watched listings of the year with broader implications for the IPO pipeline.

UnitedHealth Forecasts Profit Above Estimates but Shares Plummet on Medicare Advantage Rate Plan

UnitedHealth Group forecast its 2026 adjusted profit slightly above Wall Street expectations, yet the company’s stock tumbled sharply after the U.S. government proposed a modest 0.09% increase in Medicare Advantage payment rates for 2027 — far below market expectations. The weak rate outlook clouded investor sentiment, triggering widespread selling in major health insurers including Humana and CVS Health and underscoring sector vulnerability to policy shifts.